Clinical Practice Guideline-inconsistent Chemotherapy-induced Vomiting Prophylaxis in Pediatric Cancer Patients in Community Settings: A Children's Oncology Group Study

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2024 Sep 6

PMID 39238137

Authors

Aaron J Sugalski

Allison C Grimes

Michelle M Nuno

Subhash Ramakrishnan

Melissa P Beauchemin

Paula D Robinson

Nancy Santesso

Alexandra M Walsh

Andrea R Wrightson

Lolie C Yu

Susan K Parsons

Lillian Sung

L Lee Dupuis

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to determine the proportion of patients receiving clinical practice guideline (CPG)-inconsistent care related to chemotherapy-induced vomiting (CIV) prophylaxis, and to describe the association between CPG-inconsistent care and site size. The association between delivery of CPG-inconsistent care and patient outcomes (CIV control, admission prolongation, and unplanned healthcare visits) was also described.

Methods: This was a retrospective study conducted at Children's Oncology Group (COG) National Cancer Institute Community Oncology Research Program (NCORP) sites. Eligible patients received highly (HEC) or moderately emetogenic chemotherapy (MEC) as inpatients from January 2014 through December 2015, and were previously enrolled in a COG study. The COG generated a patient list from which patients were randomly selected for chart review by participating sites. A central panel adjudicated CIV prophylaxis received as CPG-consistent or -inconsistent.

Results: Twenty-four sites participated. Over half of patients received CPG-inconsistent CIV prophylaxis (HEC: 59/112, 52.6%; MEC: 119/215, 55.3%). The most common reasons for CPG-inconsistency were shortened duration of antiemetic administration or omission of dexamethasone. Site size was not found to be associated with CPG-inconsistent care delivery (HEC: adjusted odds ratio [OR]: 0.96, 95% confidence interval [CI]: 0.76-1.23; MEC: adjusted OR: 1.07; 95% CI: 0.92-1.24). Additionally, there was no statistically significant association between receipt of CPG-inconsistent care and patient outcomes.

Conclusions: Patients receiving MEC or HEC often received CPG-inconsistent CIV prophylaxis. Site size was not associated with receipt of CPG-inconsistent care. Future studies should evaluate strategies to improve CIV control among pediatric oncology patients including those aimed at improving CPG adherence.

Citing Articles

A roadmap to implementing machine learning in healthcare: from concept to practice.

Yan A, Guo L, Inoue J, Arciniegas S, Vettese E, Wolochacz A Front Digit Health. 2025; 7:1462751.

PMID: 39906065 PMC: 11788154. DOI: 10.3389/fdgth.2025.1462751.

References

Aapro M, Caprariu Z, Chilingirov P, Chrapava M, Curca R, Gales L . Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO). Eur J Cancer. 2022; 166:126-133. DOI: 10.1016/j.ejca.2022.01.028. View

Kent E, Mitchell S, Castro K, DeWalt D, Kaluzny A, Hautala J . Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology. J Clin Oncol. 2015; 33(24):2705-11. PMC: 4559611. DOI: 10.1200/JCO.2014.60.6210. View

Nieuwlaat R, Bertil Olsson S, Lip G, Camm A, Breithardt G, Capucci A . Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007; 153(6):1006-12. DOI: 10.1016/j.ahj.2007.03.008. View

Herrstedt J, Clark-Snow R, Ruhlmann C, Jordan K, Scotte F . MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update. Support Care Cancer. 2023; 32(1):57. DOI: 10.1007/s00520-023-08219-y. View

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020; 38(24):2782-2797. DOI: 10.1200/JCO.20.01296. View

Wockel A, Kurzeder C, Geyer V, Novasphenny I, Wolters R, Wischnewsky M . Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients. Breast. 2010; 19(2):120-7. DOI: 10.1016/j.breast.2009.12.006. View

Connor L, Dean J, McNett M, Tydings D, Shrout A, Gorsuch P . Evidence-based practice improves patient outcomes and healthcare system return on investment: Findings from a scoping review. Worldviews Evid Based Nurs. 2023; 20(1):6-15. DOI: 10.1111/wvn.12621. View

Brokamp C, Beck A, Goyal N, Ryan P, Greenberg J, Hall E . Material community deprivation and hospital utilization during the first year of life: an urban population-based cohort study. Ann Epidemiol. 2018; 30:37-43. PMC: 6370517. DOI: 10.1016/j.annepidem.2018.11.008. View

Fisher B, Robinson P, Lehrnbecher T, Steinbach W, Zaoutis T, Phillips B . Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. J Pediatric Infect Dis Soc. 2017; 7(3):191-198. DOI: 10.1093/jpids/pix030. View

10.

Beauchemin M, Sung L, Hershman D, Weng C, Dupuis L, Schnall R . Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. Support Care Cancer. 2020; 28(10):4761-4769. PMC: 7375924. DOI: 10.1007/s00520-020-05310-6. View

11.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

12.

Aapro M, Molassiotis A, Dicato M, Pelaez I, Rodriguez-Lescure A, Pastorelli D . The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012; 23(8):1986-1992. DOI: 10.1093/annonc/mds021. View

13.

Mertens W, Higby D, Brown D, Parisi R, Fitzgerald J, Benjamin E . Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003; 21(7):1373-8. DOI: 10.1200/JCO.2003.08.118. View

14.

Abunahlah N, Sancar M, Dane F, Ozyavuz M . Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. Int J Clin Pharm. 2016; 38(6):1464-1476. DOI: 10.1007/s11096-016-0393-3. View

15.

Patel P, Robinson P, Cohen M, Devine K, Gibson P, Holdsworth M . Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. Pediatr Blood Cancer. 2022; 69(12):e30001. DOI: 10.1002/pbc.30001. View

16.

Wintrobe M, HUGULEY Jr C . Nitrogen-mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders. Cancer. 1948; 1(3):357-82. DOI: 10.1002/1097-0142(194809)1:3<357::aid-cncr2820010303>3.0.co;2-v. View

17.

Paw Cho Sing E, Schechter T, Ali M, Sung L, Dupuis L . Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation. J Pediatr Hematol Oncol. 2018; 40(5):e278-e282. DOI: 10.1097/MPH.0000000000001186. View

18.

Gilmore J, Peacock N, Gu A, Szabo S, Rammage M, Sharpe J . Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract. 2013; 10(1):68-74. DOI: 10.1200/JOP.2012.000816. View

19.

Dupuis L, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P . Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011; 57(2):191-8. PMC: 6554029. DOI: 10.1002/pbc.23114. View

20.

Vazquez S, Gold J, Spirollari E, Akmal S, Hanft S . The story of dexamethasone and how it became one of the most widely used drugs in neurosurgery. J Neurosurg. 2023; 140(4):1191-1197. DOI: 10.3171/2023.9.JNS231099. View